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ZACHARY T. BLOOMGARDEN, MD
T
h i si st h eﬁrst of four reports on the
8th Annual World Congress on
Insulin Resistance, Diabetes, and
Cardiovascular Disease, held on 4–6N o -
vember 2010, in Los Angeles, California.
INSULIN RESISTANCE: NEW
CONCEPTS—Gerald Reaven (Stanford,
CA) opened the meeting with a discussion
of the implications of insulin resistance and
of the interrelationships between hyper-
insulinemia, hypertension, and cardiovas-
cular disease (CVD). In his studies, insulin
resistance is estimated fromthe steady-state
plasma glucose (SSPG) during infusion
of somatostatin, insulin, and glucose. In
a study of 490 nondiabetic individuals,




pointed out that there is an “enormous
degree” of interindividual difference at
any level of BMI or waist circumference,
with obesity accounting for only approxi-
mately one-quarter of the variation in in-
sulin sensitivity. Fitness, measured by the
maximal oxygen consumption during
exercise, was responsible for another
quarter of the variation in his studies,
with the remainder presumably caused
bygeneticfactors.Hypertensionischarac-
teristicallyassociatedwithglucoseintoler-
ance, with hyperinsulinemia, and with
roughly a 50% reduction in insulin sensi-
tivity, unaffected by antihypertensive
treatment; Reaven reviewed a study of
both treated and untreated hypertensive
individuals, showing that 34 and 39%, re-
spectively, had intermediate and that 52
and 47% had low insulin sensitivity, with
the minority being insulin sensitive. Posi-
tive family history of hypertension is also
associated with insulin resistance, with el-
evated fasting insulin levels associated
with development of essential hyperten-
sion (1). Similarly, hyperinsulinemia was
associated with abnormalities of lipid and
blood pressure levels in children and ado-
lescents (2). In a study Reaven performed
in an Italian population, insulin resistance
was associated with higher levels of BMI,
fasting glucose, insulin, and triglyceride
levels and with lower HDL cholesterol
levels,leadingReaventosuggestthatthose
with insulin resistance “are the group who
have all the cardiovascular risk factors.”
Among normotensive individuals, those
with a positive family history of hyper-
tension have similarly higher insulin and
triglyceride and lower HDL cholesterol
levels. Comparing hypertensive indivi-
dualswithabnormalversusnormalelectro-
cardiograms, the former, Reaven said, had
hyperinsulinemia and higher SSPG, lead-
ingtohissuggestionthat“insulinresistance
predict[s] heart disease.” Furthermore,
in a study of normotensive and hyperten-
sive individuals, those with low triglycer-
ide and high HDL cholesterol had no
increase in CVD with hypertension, while
those with the insulin resistance lipid pat-
tern of high triglyceride and low HDL
cholesterolhadincreasedCVD,whichfur-
ther worsened with hypertension (3). Hy-
pertension and insulin resistance both are
associated with increased mononuclear
cell adhesion to the endothelium, and
asymmetric dimethyl arginine, an inhibi-
torofnitricoxide(NO)synthase(NOS),is
elevated with insulin resistance, with or
without hypertension. Heart rate corre-
lates with the insulin response to glucose
challenge and with SSPG, suggesting a re-
lationship between insulin resistance and
enhanced sympathetic nervous system
activity, and sensitivity of blood pressure
to a sodium load is more strongly pre-
dicted by hyperinsulinemia than by
changes in renin, aldosterone, or atrial na-
triuretic peptide, with sodium sensitivity
associatedwithweightgainandwithlesser
increase in NO to vasodilatory stimuli.
Taken together, Reaven concluded, the in-
sulin resistance and associated metabolic
abnormalities present in hypertension, in
thosedevelopinghypertension,andinrel-
atives ofhypertensiveindividualsbothex-
plain its pathogenesisand are related toits
association with CVD.
In a second lecture at the meeting,
Reaven suggested that “the concept of in-
sulin resistance is not as simple as the
words themselves.” He termed compen-
satory hyperinsulinemia “the overlooked
villain” and pointed out that insulin ac-
tion varies as a function of organ system
and insulin dose-response relationships.
Adipose tissue is more sensitive to insulin-
induced suppression of lipolysis than is
muscle to stimulation of glucose uptake,
he pointed out, an example of important
differences in dose-response curves of
different tissues, explaining the ﬁnding
of elevated fasting but not postprandial
free fatty acid (FFA)—as opposed to the
much greater differences in postprandial
than in fasting glucose in type 2 diabetes.
Furthermore, neither the sympathetic
nervous system nor the kidney is resis-
tant to insulin action; insulin resistance
is associated with increased sympathetic
tone, and high dietary sodium induces el-
evated blood pressure in insulin-resistant
states. Insulin resistance, hyperinsulinemia,
and urate have a complex relationship,
Reaven said, with insulin resistance re-
ducing urate clearance and leading to
higher urate concentrations. The liver
should be considered separately in terms
of glucose homeostasis and lipid metab-
olism. Hepatic glucose production is
not elevated in type 2 diabetes at glucose
levels below ;180 mg/dL and is mod-
estly increased above this level, to a
degree equal, he noted, to the rate of gly-
cosuria, although it might be considered
inappropriately high for the degree of
hyperglycemia. Hepatic insulin resistance
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PERSPECTIVES ON THE NEWSshould be differently understood in terms
of lipid metabolism. Elevated fasting
FFAs in turn increase VLDL secretion
and, hence, plasma triglyceride levels,
with no hepatic resistance to insulin inhi-
bitionoftriglyceridesecretion.Finally,the
ovary appears to be more insulin sensitive
to testosterone production in polycystic
ovary syndrome (PCOS); perhaps ovarian
hypersensitivity to insulin is required for
the condition to appear.
Bart Staels (Lille, France) discussed
the contemporary clinical role of the
peroxisome proliferator–activated recep-
tor (PPAR) system, focusing on new ago-
nists. The PPARs are nuclear regulators of
energy homeostasis, lipid and glucose
metabolism, and inﬂammation, suggest-
ing roles as modulators of the metabolic
syndrome,type 2 diabetes,and its cardio-
vascularcomplications.PPARa,thetarget
of the ﬁbrates, plays a role in fatty acid
oxidation, triglyceride lowering, and
HDL raising, acting mainly in liver; PPARg
is insulin sensitizing and glucose and lipid
lowering, acting mainly in adipose tissue;
andPPARd,“thestillenigmaticPPAR,”also
plays roles in lipoprotein and energy me-
tabolism, acting mainly in skeletal muscle.
Staels raised the question of whether
ﬁbrate PPARa agonists might reduce the
“residual risk” seen after maximal dose
statin treatment by further lowering LDL
and raising HDL cholesterol or, perhaps,
by other actions. Fibrates increase triglyc-
eride and remnant lipoprotein metabo-
lism, reducing apolipoprotein (apo)C-III
production, increasing triglyceride clear-
ance,andincreasinghepaticmitochondrial
fatty acid b-oxidation, which increases tri-
glyceride degradation. PPARa agonists
controlHDLcholesterolproductionbyin-
creasing transcription of apoA1 and, also,
by decreasing transcription of serum am-
yloid A, increasing the anti-inﬂammatory
HDL cholesterol effect (4,5). PPARa
may also play a role in intestinal choles-
terol homeostasis, increasing apoA1 and
ABCA1geneexpressioninhumanjejeunal
specimens.
The Veteran’s Administration HDL
Intervention Trial is the only study car-
ried out in men with coronary heart dis-
ease whose primary lipid abnormality
was a low HDL cholesterol level and did
show that gemﬁbrozil reduced risk in di-
abetic patients (6). Reviewing the post
hoc but consistent analysis ﬁnding of
the Helsinki Heart Study, Bezaﬁbrate In-
tervention Program, and Action to Con-
trolCardiovascularRiskinDiabetesstudy
(ACCORD) that the degree to which
ﬁbrates decrease cardiovascular risk is
greatest in those with lower HDL cho-
lesterol and higher triglyceride levels,
Staels analyzed this phenomenon in the
Fenoﬁbrate Intervention and Event Low-
ering in Diabetes (FIELD) Study (7). Fur-
thermore,Staelsstated,“thesecompounds
have potential not only to have effect in
macrovascular complications,” reviewing
the ﬁnding from FIELD that fenoﬁbrate
decreased microvascular and cardiovas-
cular complications independent of gly-
cemia (8), with a similar ﬁnding in the
ACCORD study of fenoﬁbrate being as-
sociated with reduction in retinopathy;
older literature also suggested that ﬁbrates
reduce retinopathy (9,10).
The action of PPARb/d involves mul-
tiple potential target tissues (11), appear-
ing to increase HDLcholesterollevelsand
to reduce postprandial triglyceride levels
by increasing their clearance (12),leading
topotentiallybeneﬁcialchangesinfasting
triglyceride, apoB, LDL cholesterol, insu-
lin, liver fat, and urinary inﬂammatory
markers (13). Staels further noted that
there is cross-talk between PPARa and
PPARd in hepatic parenchymal cells and
in macrophages (14).
PPARg agonists, which Staels termed
“the [glucose-lowering] compounds with
the most durable action,” have undesir-
able associations with edema, body weight
gain, and skeletal fractures. Each PPAR
compound, however, appears to have
distinct pharmacological activity. When
fenoﬁbrate is compared with gemﬁbrozil,
the latter markedly increases homocys-
teine; in a comprison of pioglitazone with
rosiglitazone, the latter increases LDL
cholesterol. There is need to develop
compounds with improved clinical efﬁ-
cacy and fewer side effects, leading to the
concept of selective PPAR modulators
(SPPARMs) (15). Compounds with new
PPAR effects include aleglitazar (16), and
Staels reviewed his studies with the dual
PPARa/d modulator GFT505, which de-
creases apoB, apoC-III, apoE, triglyceride,
and hepatic enzyme levels (suggesting
beneﬁt in nonalcoholic fatty liver disease);
increases HDL cholesterol; and improves
glucose homeostasis in individuals with
impaired fasting glucose and impaired
glucose tolerance. “There is future in this
ﬁeld of PPAR agonism,” Staels concluded.
Philip Tsao (Stanford, CA) discussed
theApelin-APJsysteminCVDandinsulin
resistance. APJ is a receptor that was ﬁrst
discovered in 1993, cloned by homology
as an orphan G–coupledpeptidereceptor
( G P C R )( 1 7 ) ;A ,P ,a n dJa r et h ei n i t i a l so f
the names of the discoverer’sc h i l d r e n .
APJ has 40–50% homology with the an-
giotensin II (AII) receptor but does not
bind AII. APJ is expressed in the cardio-
vascular system, central nervous system,
skeletal muscle, adipose tissue, and liver.
Apelin was identiﬁed in 1998 as the re-
ceptor’sagonist.Itsprecursorisa77amino
acid peptide, with 12, 13, and 36 amino
acid isoforms. The expression of apelin
in numerous tissues; in the endothelium;
in neurons, including those of the hypo-
thalamus; and in adipocytes suggests that
it has both endocrine and paracrine ef-
fects. Apelin is the most potent inotrope
known. All its isoforms decrease blood
pressure in animal models, and human
studies show endothelium-dependent re-
duction in blood pressure, an effect de-
creased by an NOS inhibitor (18). Apelin
alsomayhavealong-termprotectiveeffect
against atherosclerosis, decreasing AII-
induced atherosclerosis. Animals not ex-
pressing apelin have decreased cardiac
contractility, and the atherosclerosis of
mice not expressing apoE is worsened by
apelin deﬁciency. Adipocyte apelin secre-
tion is dependent on insulin in vitro (19)
and its levels correlate with BMI in human
studies(20),butintriguingly,apelinadmin-
istration increases insulin sensitivity (21).
Mice not expressing apelin have increased
fasting insulin, decreased adiponectin,
andinsulinresistance.Insulin-inducedin-
sulin receptor substrate (IRS)-1 and Akt
phosphorylation are reduced in these ani-
mals, and the insulin resistance is wors-
enedwithahigh-fatdiet,aneffectreversed
by infusion of apelin in vivo and in vitro.
In db/db mice, apelin treatment improves
insulin and glucose levels. Apelin, then,
acts on skeletal muscle to increase insulin
signaling, glucose uptake, and muscle
blood ﬂow. It also reduces FFA levels and
lowers isoproterenol-induced adipocyte
FFA release, with mice not expressing
apelin having increased visceral fat and in-
creased intramyocellular triglyceride. This
effect appears to involve hormone-sensitive
lipoprotein lipase and AMP kinase (AMPK)
activation to increase intracellular cAMP
levels.
Richard Johnson (Denver, CO) pre-
sented evidence of a relationship of
fructose and uric acid to the pathogenesis
of diabetes and obesity. He recalled the
thrifty gene hypothesis (22) that evolu-
tionary adaptations to lack of nutrient
availability underlie many of our meta-
bolic characteristics and noted that the
increase in sugar intake over the past sev-
eral centuries (23) leads to adaptations
e116 DIABETES CARE, VOLUME 34, JULY 2011 care.diabetesjournals.org
Perspectives on the Newswith desirable effects under circum-
stances of famine to engender the develop-
ment of illness. Sucrose is a disaccharide
of glucose and fructose, and high fructose
corn syrup is a mixture of 55% fructose
and 45% glucose. Fructose itself appears
naturallyinfoodssuchashoney,andfruc-
tose availability is increasing in our mod-
ern environment of low physical activity,
high energy intake, and obesity. The spe-
ciﬁc mechanisms by which fructose
causesadverseeffectsrelatetoitsunique
metabolism, with a speciﬁc transporter
and with fructokinase, which catalyzes the
phosphorylation of fructose to fructose-1-
phosphate (F1P), not being product regu-
lated, which potentially leads to transient
ATP depletion (24).
Fructose has effects on the kidney
(25), adipocytes, the vasculature, inﬂam-
mation, and liver (26). It induces meta-
bolic syndrome characteristics not seen
with pair feeding of equicaloric diet given
as starch (27), and even when calories are
restricted but dietary sucrose levels are
increased, Johnson showed animal mod-
els in which features of metabolic syn-
drome such as visceral obesity and fatty
liver develop. When healthy men are
given a diet adding 200 g fructose daily
for 2 weeks, fasting triglyceride increased
55%, with increases in weight and blood
pressure, reduction in HDL cholesterol,
and reduction in insulin sensitivity (28).
“Fructose,” Johnson said, “correlates with
the rise in metabolic syndrome through-
out the world.”
Soft drink consumption is increasing
(29), correlating with increasing preva-
lence of gout, metabolic syndrome, and
nonalcoholic fatty liver disease (30).
Johnsonreviewedstudiesofhypertension
inassociationwithgoutdatingfrommore
than a century ago (31), with extensive
subsequent corroborative evidence, al-
though this correlation does not demon-
strate a causal relationship of urate to
hypertension. Stronger evidence comes
from inhibition of uricase, the enzyme
that degrades urate to allantoin, which
functions in most mammals other than
man. Administration of an inhibitor of
this enzyme to rodents leads to a blood
pressure increase, which can be pre-
vented by allopurinol or probenecid ad-
ministration(32).Inanimalmodels,urate
activates the renal renin-angiotensin sys-
tem,inducesintracellularoxidativestress,
inhibits NO, induces inﬂammation, and
induces AII. Hyperuricemia induces pre-
glomerular vascular disease, leading to
sodium-sensitive hypertension (33),
which appears to be an early phase of hy-
pertension, with low volume and renin
dependency (34).
Serumurateiselevatedinadolescents
with newly diagnosed hypertension (35),
and studies with allopurinol and with
probenecid treatment in newly diagnosed
hypertension in this age-group show
blood pressure reduction, particularly in
those whose urate level decreased below
5 mg/dL (36). Further evidence of urate-
dependence of hypertension has been
shown in a rodent model with fructose
feeding (37), leading Johnson to wonder
whether urate is “the catalyst that then
leadstosalt-sensitivehypertension.”Allo-





induced by sucrose, insulin deﬁciency, is-
let hyalinosis, and inﬂammation develop
in association with upregulation of the is-
let urate transporter, suggesting that islet
injury from fructose is in part mediated
by urate. In preliminary studies, agents
to block fructokinase lessen fructose-
induced diabetes (40), while fructose
increases fructokinase activity, a phenom-
enon also observed in nonalcoholic fatty
liverdiseasemodels,withthefructokinase
upregulation dependent on uric acid. Re-
turning to the thrifty gene hypothesis,
Johnson suggested that the diet of early
hominids was high in fruits and hence in
fructose but that periods of famine led to
survival beneﬁt of uricase deﬁciency be-
cause of the beneﬁcial effect of insulin re-
sistanceinincreasingfatstorage.Today,of
course,thesamemechanismsincreaserisk
of diabetes and obesity.
Grahame Hardie (Dundee, U.K.) dis-
cussed AMPK, stating with tongue in
cheek, “If it’s good for you, it must acti-
vate AMPK.” AMPK levels are modulated
by a number of drugs, including AICAR,
biguanides, thiazolidinediones, resvera-
trol, epigallactechin gallate (in green tea),
berberine (from Chinese Goldthread),
and an agent in development by Abbott,
A-769662. Cytokines acting on AMPK in-
clude leptin and adiponectin, the latter
perhaps mediating effects of thiazolidine-
diones. French lilac or Goat’s Rue, galaga
ofﬁcinalis, was used as an herbal remedy
in medieval Europe. In 1923, its active
component was identiﬁed as the guani-
dine derivative galegine,leading tothe de-
velopment of biguanide derivatives in the
1950s. Hardie reviewed the evidence that
AMPK activation mediates the therapeutic
action of metformin. In a rodent model
notexpressingtheserine/threoninekinase
LKB1, AMPK is not activated by metfor-
min and does not have hypoglycemic
effect (41). In a study of 1,024 diabetic
patients, the analysis of single nucleotide
polymorphisms associated with the abil-
ity of metformin to reduce A1C, a locus
on chromosome 11 linked to a different
protein kinase, ATM (of the atypical
phosphatidyl-inositol-3-kinase-like [PIKK]
family) was found to be a marker (42).
ATM mutation is the defect in human
Ataxia telangiectasia. It is activated by
double-strand DNA breaks, in turn acti-
vating AMPK, and is involved in DNA re-
pair. ku55933 is an ATM inhibitor and
inhibitsactivationofAMPKbymetformin,
blocking its glucose-lowering effect (43).
Metformin’s activation of AMPK requires
intact cells. Hardie pointed out that both
biguanides metformin and phenformin
are inhibitors of complex I of the respira-
tory chain,suggesting that their effect isto
increase the cellular AMP-to-ATP ratio
and indirectly activate AMPK. The three-
dimensional structure of AMP binding to
AMPK has been elucidated (44). In a cel-
lular model with AMP-insensitive AMPK,
oligomycin fails to activate AMPK, while
the direct activator A769662 remains ef-
fective,leadingtotheconceptthatmetfor-
min is “a metabolic poison” that has this
beneﬁcial effect.
INSULIN RESISTANCE AND
CANCER—Hardie turned to new stud-
ies of AMPK activators and cancer. Breast
and colorectal cancers are particularly
associated with obesity and insulin re-
sistance. AMPK activation causes cell
cyclearrestincancercells,withthetumor
suppressorlkb1akeyupstreamkinasefor
AMPK and with evidence that AMPK
turns off target of rapamycin (mTOR),
which is hyperactivated in many tumors.
In breast tumors, AMPK activation is re-
duced, a possible mechanism of cancer
development suggesting the potential
beneﬁtofmetformin.Diabeticindividuals
treatedwithmetforminhavelowercancer
incidence, and metformin delays cancer
development in a variety of animal mod-
els (45). Hypotheses are that AMPK has a
direct cell cycle effect or, alternatively,
that metformin activated hepatic AMPK,
reducing glucose, insulin, and IGF1,
which lead to the anticancer effect, al-
though in non–insulin resistant animal
models metformin has been shown to be
cancer reducing. Thus, AMPK monitors
the cellular AMP-to-ATP ratio and acts
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AMPK activation switching cell function
away from anabolism, growth, and pro-
liferation toward catabolism and quies-
cence. AMPK is the target for metformin
and other factors, and metformin acts by
inhibiting mitochondrial function and in-
creasing the AMP-to-ATP ratio. As AMPK
activation is decreased in many cancers,
the beneﬁt of metformin in cancer treat-
ment may be limited; another factor may
be decreased levels in cancer cells of the
organic cation transporters required for
metformin cellular uptake.
Lorraine Lipscombe (Toronto, Canada)
reviewed the evidence of an association
between diabetes and cancer and the
importance of insulin resistance (rev. in
[46]). The association of diabetes and
cancer has long been suspected, although
the ﬁrst prospective study, carried out by
Elliot Joslin, failed to show an association,
perhaps because of the high prevalence of
type 1 diabetes in his clinic (47). Numer-
ous large databases have subsequently
revealed a cancer association for type 2
but not for type 1 diabetes. The initial re-
ports were of association with pancreatic
cancer, with the higher rates in indivi-
duals with longer duration of diabetes
suggesting a real causal relationship.
Hepatocellular cancer is associated with
diabetes in the absence of risk factors
such as hepatitis C and may be a conse-
quence of nonalcoholic steatohepatitis
cirrhosis. Endometrial cancer has long
been recognized to be associated with
obesity, likely from increased adipose tis-
sue estrogen production, but an effect of
diabetes independent of obesity has been
demonstrated and there is evidence of
effects of diabetes on colorectal cancer.
Lipscombe reviewed her study comparing
nearly 75,000 diabetic women with con-
trol subjects, showing 2.85 vs. 2.64 breast
cancer cases per 1,000 person-years, an
8% increase, controlling for obesity and
other risk factors (48), so that “diabetes
or something about diabetes may be con-
tributing to an increased risk of breast
cancer.” In a meta-analysis, diabetes was
found to be particularly associated with
carcinoma of the liver, pancreas, kidney,
andendometrium;somewhatlessstrongly
associated with colon and bladder can-
cers; and still less associated with non-
Hodgkins lymphoma (49). Another study
showed the strongest association to be be-
tween colorectal and pancreatic cancers
(50).Thesamemeta-analysisshowedpan-
creas.colon.breastcancerassociations
with serum insulin and C-peptide and a
nonsigniﬁcant trend for endometrial can-
cer. It is interesting that prostate cancer
risk is reduced among diabetic men,
which Lipscombe suggested might be re-
lated to their higher rate of hypogonadism.
Potential mechanisms of diabetes-induced
malignancy include a direct effect of hy-
perglycemia or an indirect relationship
caused by insulin resistance, inﬂamma-
tion, lipid and fatty acid abnormalities,
adipokines, or IGF-1. The Warburg hy-
pothesis that cancer cells predominantly
use glycolysis for energy and have high
glucose requirement (51) suggests that
hyperglycemia might create a favorable
environment for cancer. A relationship
of intensive glycemic control to cancer
and cancer mortality has not, however,
been demonstrated, while the hyper-
insulinemia hypothesis is supported by
the 30% greater likelihood of malignancy
among diabetic individuals treated with
sulfonylureas and the 90% increase with
insulin compared with metformin (52).
Diabetes, Lipscombe commented, is also
associated with worse prognosis among
individualswithcancer,whichmayreﬂect
an effect of hyperinsulinemia or may be
due to less aggressive cancer treatment
among patients with diabetes, lower like-
lihood of screening in this group, or
reduced survival rates because of other
diabetes complications.
Pamela Goodwin (Toronto, Canada)
further discussed interrelationships of
insulin with malignancy and the effects
of metformin. Higher BMI is associated
with greaterrisk ofdistantrecurrenceand
mortality from breast cancer, with poten-
tial mediators including inﬂammation,
adipokines, insulin, IGFs, and estrogens,
all of which may interact. Higher insulin
levels correlate with mortality among
women with breast cancer (53) and men
with prostate cancer (54). Cancers may
express high levels of insulin, IGF-1,
and hybrid receptors (55), and higher in-
sulin receptor (insulin resistance) expres-
sion is associated with worse outcome
(56). The a isoform expressed in breast
cancer is the fetal receptor, which binds
IGF1 and IGF2 and may switch insulin
frommetabolictomitogenicandanabolic
actions (49). Goodwin reviewed her
study showing that metformin reduces
cancer risk (57), agreeing with the other
speakers’ comments that it may act by
lowering insulin levels and in an insulin-
independent fashion, directly suppress-
ing mammary tumor growth (58,59).
Metformin activates AMPK and may
have other cellular effects, upregulating
cell cycle–associated genes and possibly
improving DNA damage recognition and
repair. Organic cation transporters are re-
quired for cellular uptake of metformin,
although the extent to which these trans-
porters are expressed in human breast
cancer is not known. Metformin has ben-
eﬁt across different subtypes of breast
cancers (60) but may be most effective in
“triple negative” breast cancer (61), with
potential to abrogate resistance to human
epidermal growth factor receptor-2–
targeted therapies (62) and to increase
aromatase inhibitor effects (63). Goodwin
also reviewed rodent models in which
metformin reduced tobacco-induced
lung carcinogenesis (64) and had beneﬁt
in prevention of colon carcinoma (65).
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